Servicio de Crecimiento y Desarrollo, Hospital de Pediatría J.P, Garrahan, Buenos Aires C1245, Argentina.
Centro de Estudio de las Metabolopatías Congénitas (CEMECO), Hospital de Niños de la Santísima Trinidad, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba X5014AKN, Argentina.
Genes (Basel). 2022 Nov 7;13(11):2063. doi: 10.3390/genes13112063.
Multiple Osteochondromatosis (MO, MIM 133700 & 133701), an autosomal dominant O-glycosylation disorder (EXT1/EXT2-CDG), can be associated with a reduction in skeletal growth, bony deformity, restricted joint motion, shortened stature and pathogenic variants in two tumor suppressor genes, and In this work, we report a cross-sectional study including 35 index patients and 20 affected family members. Clinical phenotyping of all 55 affected cases was obtained, but genetic studies were performed only in 35 indexes. Of these, a total of 40% ( = 14) had a family history of MO. Clinical severity scores were class I in 34% (:18), class II in 24.5% (:13) and class III in 41.5% (:22). Pathogenic variants were identified in 83% (29/35) probands. We detected 18 (62%) in and 11 (38%) in . Patients with variants showed a height z-score of 1.03 SD lower than those with variants and greater clinical severity (II-III vs. I). Interestingly, three patients showed intellectual impairment, two patients showed a dual diagnosis, one Turner Syndrome and one hypochondroplasia. This study improves knowledge of MO, reporting new pathogenic variants and forwarding the worldwide collaboration necessary to promote the inclusion of patients into future biologically based therapeutics.
多发性骨软骨瘤病(MO,MIM 133700 和 133701),一种常染色体显性 O-糖基化疾病(EXT1/EXT2-CDG),可伴有骨骼生长减少、骨畸形、关节运动受限、身材矮小和两个肿瘤抑制基因的致病性变异,和。在这项工作中,我们报告了一项包括 35 名指数患者和 20 名受累家庭成员的横断面研究。对所有 55 例受累病例进行了临床表型分析,但仅对 35 名指数进行了遗传研究。其中,共有 40%(=14)有 MO 的家族史。临床严重程度评分 34%(:18)为 I 级,24.5%(:13)为 II 级,41.5%(:22)为 III 级。在 83%(29/35)的先证者中发现了致病性变异。我们在 中检测到 18 个(62%),在 中检测到 11 个(38%)。携带 变异体的患者的身高 z 分数比携带 变异体的患者低 1.03 个标准差,且临床严重程度更高(II-III 比 I)。有趣的是,有 3 名患者表现出智力障碍,2 名患者表现出双重诊断,1 名特纳综合征和 1 名软骨发育不全。这项研究提高了对 MO 的认识,报告了新的致病性变异,并推动了全球合作,以促进将患者纳入未来基于生物学的治疗。